The raise comes a month after the Cambridge, Massachusetts-based firm's launch with a $20 million Series A round. Black Diamond is developing drugs that target allosteric mutant oncogenes, which it describes as an unexplored space.
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.